Develop and validate immuno- and enzymatic biomarker assays to support preclinical and clinical studies under GLP standards.

Manage a Core Laboratory utilizing a variety of quantitative immuno assay technologies and automated liuid handling to support clinical studies and immuno assay development.

Managed Protein Biomarker personnel while working closely with customers to deliver high quality data within tight timelines.Validated and quantified numerous multiplexed assay panels, ELISA’s and activity assays including over 100 biomarkers.Programmed and validated a variety of automated liquid handling devices to develop a highly efficient biomarker testing process. Scheduled fully automated runs with CLARA scheduling software.Identified significant biomarker changes with statistical analysis routines including ANOVA, ANCOVA, Matched Pairs analyses, Cluster analyses and Dunnett’s test with SAS, JMP.Supported preclinical drug profiling and efficacy studies from rodent models involving metabolic drug targets of high interest.Supported numerous epidemiology and efficacy clinical studies including liver fibrosis, Diabetes, COPD and Alzheimer's.Developed and optimized a 384-well myosin heavy chain immuno-assay as a sarcopenia screen.

Developed, optimized, and delivered numerous immuno and activity based protein assays to support global drug discovery in multiple therapeutic areas including metabolic, oncology, viral, and cardiovascular disease.Created and developed Visual Basic for Applications software, AED (Automated Experimental Design) to decrease biochemical assay development time up to 10 fold by working in conjunction with span-8 Liquid Handling Instruments.Wrote “In Flight” data analyses and cherry picking software for fully automated assays on an ORCA rail to locate and transfer up to 2000 positive wells into master plates per day.

Affected the acceptance of Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) assay technology at Glaxo Wellcome by comparing ELISA and TR-FRET src kinase assays against 40,000 compounds.Worked as part of a team which successfully built a fully automated system to screen up to forty four 96 well MTP’s per day in any combination of 1 to 4 independent kinase assays.

Set up solid tumor models in rodents and characterized efficacy of topoisomerase I inhibitors in rodent models.Participated in IND report for a topoisomerase I inhibitor taken to clinical trials for the treatment of solid tumors.

Scaled up and increased the yield of calf thymus topoisomerase I purification to support high-through-put assays testing up to 10,000 compounds per month.Set up and performed gel-based and tissued culture-based screensfor Topoisomerase I inhibitors.

Lipid second messanger research.Purified Topoisomerase II from calf thymus.Set up and performed gel-based Topoisomerase II screens.

Tissue CultureMurine retrovirus research

Drosophila researchPlasmid and genomic DNA prufication